Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...
Despite the trial's failure, Alector secured a $50 million credit facility from Hercules Capital (NYSE:HTGC) Inc., aimed at supporting ongoing research and development efforts. The company ...
Arnon Rosenthal, the Chief Executive Officer of Alector, Inc. (NASDAQ:ALEC), recently reported the sale of 52,172 shares of the company's common stock, totaling approximately $131,442. The sale ...
As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
A study by the team of Prof. Kristel Sleegers (VIB-UAntwerp), published in Acta Neuropathologica, has offered new insights into the genetic factors that drive Alzheimer’s disease. Using samples from ...
And the first IPO without a fixed share price since the shutdown ended late last month was from Alector, a biotech that is aiming to find new treatments for dementia. Alector fell on its trading ...
The company is also running mid-stage trials of ABBV-552, an SV2A modulator, which is being evaluated to enhance synaptic efficiency in Alzheimer's, and Alector-partnered TREM2-directed antibody ...